Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia.
|Videos|September 25, 2012
Photos From the American Thyroid Association Annual Meeting
Author(s)Onclive Team
Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.
Advertisement
A collections of photos from both the 82nd Annual Meeting of the American Thyroid Association and Quebec City, Canada, the city that hosted the latest installment of the annual meeting from September 19-23, 2012.
The 2012 ATA meeting focused on the latest promising clinical and translational research into thyroid diseases and disorders. The speakers addressed recent advances in thyroidology, molecular markers and panels, targeted therapies, and optimal surgical stategies.
<<<
Advertisement
Related to this article
The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.
Prophylactic tocilizumab before step-up dosing lowered CRS rates approximately 5-fold with teclistamab and talquetamab in relapsed/refractory myeloma.
Rusfertide preserved efficacy and safety benefits over placebo in both low- and high-risk polycythemia vera.
In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.
A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Daraxonrasib in Pancreatic Cancer
2
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
3
Time-Limited Pirtobrutinib-Based Triplet Yields High Rates of Undetectable MRD in First-Line CLL
4
Dr Sallman on Next Steps for Ofirnoflast in Lower-Risk MDS
5